Validation of the global resource of eczema trials (GREAT database)

BMC Dermatology

Volumn 15, Issue 1, 2015, Pages 1-

  Nankervis, Helen ^a   Devine, Alison ^b   Williams, Hywel C ^a   Ingram, John R ^c   Doney, Elizabeth ^d   Delamere, Finola ^d   Smith, Sherie ^a   Thomas, Kim S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b GLAN CLWYD HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Atopic dermatitis; Database; Eczema; Randomised controlled trials; Validation

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE;

ACCESS TO INFORMATION; ARTICLE; BIBLIOGRAPHIC DATABASE; DIET THERAPY; ECZEMA; GLOBAL RESOURCE OF ECZEMA TRIALS DATABASE; HERBAL MEDICINE; HOMEOPATHY; HUMAN; PATIENT EDUCATION; PSYCHOTHERAPY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); VALIDATION STUDY; DERMATITIS, ATOPIC; FACTUAL DATABASE; LITERATURE; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; DATABASES, FACTUAL; DERMATITIS, ATOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; SENSITIVITY AND SPECIFICITY;

EID: 84928228189     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/s12895-015-0024-z     Document Type: Article

References (38)

1. Williams HC, Wuthrich B. In: Williams HC, editor. Atopic Dermatits, vol. 1. Cambridge: Cambridge University Press; 2000.
2. Nankervis H, Maplethorpe A, Williams HC. Mapping randomized controlled trials of treatments for eczema-the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010). BMC Dermatol. 2011;11:10.
3. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1-191.
4. Mapping of systematic reviews of atopic eczema. [http://www.nottingham. ac.uk/research/groups/cebd/documents/methodological-resources/ maponaewebsitefeb2013.pdf]
5. Futamura M, Thomas KS, Grindlay DJC, Doney EJ, Torley D, Williams HC. Mapping systematic reviews on atopic eczema-an essential resource for dermatology professionals and researchers. PLoS ONE. 2013;8(3):e58484.
6. Ashcroft DM, Chen LC, Garside R, Stein K, Williams HC. Topical pimecrolimus for eczema. Cochrane Database Syst Rev. 2007;4:CD005500.
7. Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database Syst Rev. 2008;1:CD005203.
8. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev. 2008;3:CD003871.
9. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;4:CD006135.
10. Ersser SJ, Latter S, Sibley A, Satherley PA, Welbourne S. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2007;3:CD004054.
11. Zhang W, Leonard T, Bath-Hextall F, Chambers CA, Lee C, Humphreys R, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2005;2:CD002291.
12. Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147(4):474-88.
13. Yin Z, Xu J, Luo D. Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: A meta-analysis. J Biomed Res. 2011;25(6):385-91.
14. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27(7):1395-406.
15. Simonart T, Kabagabo C, De Maertelaer V. Homoeopathic remedies in dermatology: a systematic review of controlled clinical trials. Br J Dermatol. 2011;165(4):897-905.
16. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and metaanalysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415-28.
17. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Aller Clin Immunol. 2001;108(4):651-2.
18. Novartis. A 4-week, randomized, multicenter, double-blind, vehiclecontrolled, parallel-group clinical trial to evaluate the efficacy and safety of pimecrolimus cream 1% in the short-term treatment of patients with mild to moderate Atopic Dermatitis (Eczema). In: Novartis Trials Database. 2005.
19. Novartis. A 6-month, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of pimecrolimus 1% cream twice daily vs. standard of care in the management of mild to severe atopic dermatitis in adults.In: Novartis Trials Database. 2005.
20. Novartis. A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of pimecrolimus cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroid. In: Novartis Trials Database; 2006.
21. Novartis. Confirmatory study in pediatric patients with atopic dermatitismulticenter, randomized, double-blind, parallel-group, vehicle-controlled study with a 26-weeks treatment phase to determine the efficacy, safety of pimecrolimus cream for long-term treatment of pediatric patients with atopic dermatitis. In: Novartis Trials Database. 2005.
22. Novartis. A multicenter, 5-week, randomized, double-blind, placebo controlled, parallel group study exploring the effects of pimecrolimus cream 1% (twice daily application) vs. placebo control (twice daily application) on the molecular and cellular profile of adult male patients with atopic dermatitis. In: Novartis Trials Database. 2006.
23. Clinical Trials Results database. [http://www.novctrd.com/ctrdWebApp/ clinicaltrialrepository/public/login.jsp]
24. Staab D, Kaufmann R, Brautigam M, Wahn U, Group CAC-S. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16(6):527-33.
25. Thaci DF-HR, Foelster-Holst R, Hoger P, Kaufmann R, Brautigam M, Weidinger G, et al. Pimecrolimus cream 1% is effective in the treatment of atopic eczema in infants irrespective of clinical score. J Eur Acad Dermatol Venereol. 2003;17 Suppl 3:2.37.
26. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223-7.
27. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig. 2006;26(5):235-46.
28. Siegfried EKN, Molina C, Kianifard F, Abrams K. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatol Treat. 2006;17(3):143-50.
29. Breneman D, Fleischer Jr A, Abramovits W, Farber H. Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2006;54(3, Suppl 1 AB88):832. Abstract.
30. Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol. 2007;98(1):51-6.
31. Larsen FS, Simonsen L, Melgaard A, Wendicke K, Henriksen AS. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol. 2007;87(1):62-8.
32. Ravenscroft JC, Layton AM, Eady EA, Murtagh MS, Coates P, Walker M, et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol. 2003;148(5):1010-7.
33. Polano MK, De Vries HR. Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica. 1960;120:191-9.
34. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992;27(1):29-34.
35. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90(5):525-30.
36. Fattah AA, El-Shiemy S, Faris R, Tadros SS. A comparative clinical evaluation of a new topical steroid 'halcinonide' and hydrocortisone in steroidresponsive dermatoses. J Int Med Res. 1976;4(4):228-31.
37. Alltrials. [http://www.alltrials.net/]
38. Transfusion evidence library. [http://evidentiapublishing.com/transfusionevidence-library/]